Advanced Hematologic Malignancies

1

Review clinical trials related to Advanced Hematologic Malignancies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.

Participants needed: 114
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Updated: Aug 11, 2025Locations: 3
Eligibility criteria

Subjects voluntarily participate in this study, sign the informed consent form,... [+13]

Patients with other malignant tumors that occurred within 3 years before the fir... [+29]